Quarterly report pursuant to Section 13 or 15(d)

Acquisitions - Schedule of Intangible Assets Acquired (Details)

v3.10.0.1
Acquisitions - Schedule of Intangible Assets Acquired (Details) - USD ($)
 3 Months Ended 7 Months Ended 10 Months Ended
Feb. 16, 2018
Nov. 17, 2017
Jun. 30, 2018
Sep. 30, 2018
Sep. 30, 2018
Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: $ 18,291,000        
Intangible assets     $ 1,838,000 $ 1,838,000  
TRx          
Business Acquisition [Line Items]          
Identifiable Intangible Assets:   $ 19,596,000      
Intangible assets         $ 1,528,000
PAI Sales & Marketing Agreement | TRx          
Business Acquisition [Line Items]          
Identifiable Intangible Assets:   $ 2,553,000      
Acquired finite-lived intangible assets, weighted average useful life (in years)   2 years      
Intangible assets         219,000
Karbinal | Acquired product marketing rights | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: $ 6,200,000        
Acquired finite-lived intangible assets, weighted average useful life (in years) 16 years        
Intangible assets       (21,000)  
AcipHex | Acquired product marketing rights | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: $ 2,803,000        
Acquired finite-lived intangible assets, weighted average useful life (in years) 10 years        
Intangible assets       283,000  
Cefaclor | Acquired product marketing rights | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: $ 7,611,000        
Acquired finite-lived intangible assets, weighted average useful life (in years) 7 years        
Intangible assets       1,320,000  
Flexichamber | Developed Technology Rights | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: $ 1,677,000        
Acquired finite-lived intangible assets, weighted average useful life (in years) 10 years        
Intangible assets       546,000  
LiquiTime Process | In Process Research and Development | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: $ 0        
Intangible assets       $ (290,000)  
Metafolin | Acquired product marketing rights | TRx          
Business Acquisition [Line Items]          
Identifiable Intangible Assets:   $ 11,987,000      
Acquired finite-lived intangible assets, weighted average useful life (in years)   15 years      
Intangible assets         1,522,000
Millipred | Acquired product marketing rights | TRx          
Business Acquisition [Line Items]          
Identifiable Intangible Assets:   $ 5,056,000      
Acquired finite-lived intangible assets, weighted average useful life (in years)   4 years      
Intangible assets         342,000
Ulesfia | Acquired product marketing rights | TRx          
Business Acquisition [Line Items]          
Identifiable Intangible Assets:   $ 0      
Acquired finite-lived intangible assets, weighted average useful life (in years)        
Intangible assets         $ (555,000)
Previously Reported | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: 16,453,000        
Previously Reported | TRx          
Business Acquisition [Line Items]          
Identifiable Intangible Assets:   $ 18,068,000      
Previously Reported | PAI Sales & Marketing Agreement | TRx          
Business Acquisition [Line Items]          
Identifiable Intangible Assets:   2,334,000      
Previously Reported | Karbinal | Acquired product marketing rights | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: 6,221,000        
Previously Reported | AcipHex | Acquired product marketing rights | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: 2,520,000        
Previously Reported | Cefaclor | Acquired product marketing rights | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: 6,291,000        
Previously Reported | Flexichamber | Developed Technology Rights | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: 1,131,000        
Previously Reported | LiquiTime Process | In Process Research and Development | Avadel          
Business Acquisition [Line Items]          
Identifiable Intangible Assets: $ 290,000        
Previously Reported | Metafolin | Acquired product marketing rights | TRx          
Business Acquisition [Line Items]          
Identifiable Intangible Assets:   10,465,000      
Previously Reported | Millipred | Acquired product marketing rights | TRx          
Business Acquisition [Line Items]          
Identifiable Intangible Assets:   4,714,000      
Previously Reported | Ulesfia | Acquired product marketing rights | TRx          
Business Acquisition [Line Items]          
Identifiable Intangible Assets:   $ 555,000